
report revenue street strensiq beat in-lin soliri sale
despit multipl headwind partial off-set kanuma continu struggl
non-gaap ep also beat lower d/sg a/tax expens full year
guidanc up strong outlook soliri gmg strensiq
today posit data pnh switch patient believ
asset offer differenti profil beyond conveni alon
compel physician patient meanwhil bd effort on-going
rebuild pipelin reiter buy npv-deriv pt
solid perform report total revenu
q/q y/i consensu volum growth y/i
fx benefit y/i partial off-set price headwind y/i
bottom line lower d/sg a/tax expens drove non-gaap ep
q/q y/i ahead consensu
manag indic expens unusu low due
lower expect transit expens relat restructur effort
soliri sale q/q y/i came in-lin consensu
vs y/i volum growth note y/i comp
impact benefit recognit defer
revenu time non-u tender order
impact clinic trial enrol
unusu low amount tender order particularli latam
contribut weaker row sale exclud impact manag
indic underli pnh ahu volum growth y/i
low doubl digit upsid gmg indic
strong start first full quarter launch march
decemb gmg patient soliri
y/i volum growth primarili germani
japan help benefit chang distributor
arrang
vs neg impact q/q tender
order previous defer revenu came
tr target
recal see note highlight initi guidanc appear
conserv thu given good perform surpris manag
decis rais full year guid today
updat guidanc call full-year revenu growth prior
mid-point vs prior consensu non-
ep rang mid-point prior bracket
consensu chang non-gaap sg op margin fx benefit
headwind estim non-gaap tax rate rang lower vs
soliri revenu guid up mid-point vs prior
steadi underli growth pnh/ahu expect high singl digit y/i
adj trial enrol increas contribut gmg manag
indic track becom best soliri launch
made substanti progress commerci front commerci polici
defin gener plan access criteria in-lin better criteria
pivot trial thu far commerci drug
 patient overal enrol onesourc educ assist program
indic meaning pipelin open case behind treat patient addit compani feel
good breadth prescrib major involv clinic
investig note initi prescript come commun neurologist
neuromuscular specialist tend concentr treatment center target
alexion manag indic still long way go given refractori
gmg patient expect launch trajectori slow anytim soon
metabol revenu guid also increas mid-point vs prior
continu strong momentum strensiq particular
busi usual brazil latam front manag indic media report see
note brazil patent situat incorrect busi usual
brazil impact ex-brazil sale note brazil becom less signific
sourc revenu total revenu
today robust data achiev non-inferior also consist trend
favor primari key secondari endpoint soliris-switch pnh patient
support strong data treatment-na pnh patient mid-march see note
believ asset larg de-risk pnh approv wide anticip street
eu regulatori submiss expect submiss japan follow
conveni big plu annual infus vs soliri question
remain whether drug would suffici differenti soliri facili
convers view numer favor robust benefit breakthrough
hemolysi evid pk-base breakthrough impress rate
breakthrough switch trial repeat hemolysi event observ soliri arm
studi transfus avoid qualiti life assess facit-fatigu score
suggest truli differenti profil like reflect label appeal
physician patient slide deck detail
manag indic even without superior claim differenti product
profil compel valu proposit payer fewer infus breakthrough hemolysi
event lower transfus burden key factor year experi
pnh launch market identifi patient help facilit rapid convers pnh
patient soliri expect compani provid updat commerical/
price strategi key focu investor view see deep dive note conduct
addit market research full profil pnh avail
page
recal mid-april announc acquisit wilson therapeut wtx-se rate
bring late-stag asset wilson diseas see note focu
rare diseas product vs platform contribut near-term believ wilson
acquisit good exampl potenti futur deal
note current cash hand bit half
use wilson transact upon close addit cash flow gener throughout
undrawn revolv capac leverag given manag current debt
ebidta level believ compani adequ financi flexibl rebuild pipelin
disciplin bd effort
reflect commerci trend rais total revenu estim
non-gaap ep estim
page
page
producteventtimingpotenti updat patent coverag phase prevent trial relaps nmosd enrol phase treatment-na adolesc adult ahu studi eu regulatori submiss data phase treatment-nav adolesc adult ahu studi singl pk-base phase bridg studi weekli sub-q phase studi second-gen sub-q phase trial proof-of-concept studi immunoglobulin nephropathi regulatori submiss decis approv addit approv addit strh analysi compani reportscompl franchisemetabol inc
page
estim estim changestrhactualconsensusa vs street mm except per share diff mm except per share data priorcurr chang chang mm except per share data priorcurr chang total total total total total total total total total opex opex opex strh analysi consensu provid last updat perform inc
page
soliri yoy yoy metabol franchis gross oper oper incom non-gaap tax incom loss net incom net gaap yoy ep exclud stock-comp item strh analysi compani report last updat mm inc
biotechnolog compani engag research develop
commerci life-transform therapeut treat patient sever ultra-rar diseas
product offer fall two broad franchis complement metabol core
alexion complement franchis soliri world first termin complement inhibitor approv
treatment patient paroxysm nocturn hemoglobinuria pnh patient atyp
hemolyt urem syndrom ahu two approv product metabol franchis includ
strensiq enzym replac therapi ert approv hypophosphotasia
kanuma also ert approv lysosom acid lipas defici lal-d alexion found
headquart cheshir ct
alexion premier orphan disease-focus biotech two franchis complement
metabol year experi complement biolog flagship product soliri
standard-of-car two ultra-rar blood disord pnh ahu deep complement pipelin
slate extend domin next decad expect share outperform
potenti upward earn revis clinical/regulatori newsflow
valuat risk
pt base sum-of-the-part sotp net-present-valu npv analysi
includ estim npv soliri cash flow pnh ahu mg strensiq cash flow
kanuma cash flow lal-d compani current net cash posit use
discount rate termin growth rate believ appropri compani
similar alexion base assumpt npv suggest fair valu
contribut pipelin candid model leav substanti room potenti upsid
alexion busi larg depend commerci success soliri strensiq kanuma
product could face intens competit newer emerg therapeut products/
class unexpect advers event could hamper accept among physician
patient
alexion launch strensiq kanuma earli stage new sale market
distribut strategi capabl metabol portfolio yet proven market size
ultra-orphan indic lal-d smaller project anticip futur sale
could significantli impact
drug-pric strategi come increas scrutini lawmak far biotech
compani abl take frequent price increas product could moder
go forward ou territori government-sponsor healthcar system pay healthcar
cost product could subject increas price reimburs pressur due price control
impos govern mani countri
alexion growth conting novel product continu label
expans new indic soliri nmo could face clinic regulatori setback
prospect growth driver critic long-term success alexion
alexion busi signific exposur fluctuat foreign currenc exchang rate
approxim two-third revenu gener outsid us past year addit alexion
could face signific challeng south america brazil argentina commod depend
economi given recent turmoil oil commod
compani mention note
yatin suneja herebi certifi view express research report accur reflect
person view subject compani secur also certifi
page
receiv direct indirect compens exchang express specif
recommend report
